Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS-Flow Cytometry Working Group

Arjan A. van de Loosdrecht; Wolfgang Kern; Anna Porwit; Peter Valent; Sharham Kordasti; Eline Cremers; Canan Alhan; Carolien Duetz; Alan Dunlop; Willemijn Hobo; Frank Preijers; Orianne Wagner-Ballon; Nicolas Chapuis; Michaela Fontenay; Peter Bettelheim; Lisa Eidenschink-Brodersen; Patricia Font; Ulrika Johansson; Michael R. Loken; Jeroen G. te Marvelde; Sergio Matarraz; Kiyoyuki Ogata; Uta Oelschlaegel; Alberto Orfao; Katherina Psarra; Dolores Subirá; Denise A. Wells; Marie C. Béné; Matteo G. Della Porta; Kate Burbury; Frauke Bellos; Vincent H. J. van der Velden; Theresia M. Westers; Leonie Saft; Robin Ireland

doi:https://doi.org/10.1002/cyto.b.22044

Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS-Flow Cytometry Working Group

Arjan A. van de Loosdrecht, Wolfgang Kern, Anna Porwit, Peter Valent, Sharham Kordasti, Eline Cremers, Canan Alhan, Carolien Duetz, Alan Dunlop, Willemijn Hobo, Frank Preijers, Orianne Wagner-Ballon, Nicolas Chapuis, Michaela Fontenay, Peter Bettelheim, Lisa Eidenschink-Brodersen, Patricia Font, Ulrika Johansson, Michael R. Loken, Jeroen G. te MarveldeSergio Matarraz, Kiyoyuki Ogata, Uta Oelschlaegel, Alberto Orfao, Katherina Psarra, Dolores Subirá, Denise A. Wells, Marie C. Béné, Matteo G. Della Porta, Kate Burbury, Frauke Bellos, Vincent H. J. van der Velden, Theresia M. Westers, Leonie Saft, Robin Ireland

Research output: Contribution to journal › Article › Academic › peer-review

18 Citations (Scopus)

Abstract

This article discusses the rationale for inclusion of flow cytometry (FCM) in the diagnostic investigation and evaluation of cytopenias of uncertain origin and suspected myelodysplastic syndromes (MDS) by the European LeukemiaNet international MDS Flow Working Group (ELN iMDS Flow WG). The WHO 2016 classification recognizes that FCM contributes to the diagnosis of MDS and may be useful for prognostication, prediction, and evaluation of response to therapy and follow-up of MDS patients.

Original language	English
Pages (from-to)	77-86
Number of pages	10
Journal	Cytometry Part B - Clinical Cytometry
Volume	104
Issue number	1
Early online date	2021
DOIs	https://doi.org/10.1002/cyto.b.22044
Publication status	Published - 15 Jan 2023

Keywords

ELN
consensus
flow cytometry
myelodysplastic syndromes
standardization

Access to Document

https://doi.org/10.1002/cyto.b.22044

Cite this

van de Loosdrecht, A. A., Kern, W., Porwit, A., Valent, P., Kordasti, S., Cremers, E., Alhan, C., Duetz, C., Dunlop, A., Hobo, W., Preijers, F., Wagner-Ballon, O., Chapuis, N., Fontenay, M., Bettelheim, P., Eidenschink-Brodersen, L., Font, P., Johansson, U., Loken, M. R., ... Ireland, R. (2023). Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS-Flow Cytometry Working Group. Cytometry Part B - Clinical Cytometry, 104(1), 77-86. https://doi.org/10.1002/cyto.b.22044

@article{0697dd69c1ce47d5996c9686a656c43b,

title = "Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS-Flow Cytometry Working Group",

abstract = "This article discusses the rationale for inclusion of flow cytometry (FCM) in the diagnostic investigation and evaluation of cytopenias of uncertain origin and suspected myelodysplastic syndromes (MDS) by the European LeukemiaNet international MDS Flow Working Group (ELN iMDS Flow WG). The WHO 2016 classification recognizes that FCM contributes to the diagnosis of MDS and may be useful for prognostication, prediction, and evaluation of response to therapy and follow-up of MDS patients.",

keywords = "ELN, consensus, flow cytometry, myelodysplastic syndromes, standardization",

author = "{van de Loosdrecht}, {Arjan A.} and Wolfgang Kern and Anna Porwit and Peter Valent and Sharham Kordasti and Eline Cremers and Canan Alhan and Carolien Duetz and Alan Dunlop and Willemijn Hobo and Frank Preijers and Orianne Wagner-Ballon and Nicolas Chapuis and Michaela Fontenay and Peter Bettelheim and Lisa Eidenschink-Brodersen and Patricia Font and Ulrika Johansson and Loken, {Michael R.} and {te Marvelde}, {Jeroen G.} and Sergio Matarraz and Kiyoyuki Ogata and Uta Oelschlaegel and Alberto Orfao and Katherina Psarra and Dolores Subir{\'a} and Wells, {Denise A.} and B{\'e}n{\'e}, {Marie C.} and {Della Porta}, {Matteo G.} and Kate Burbury and Frauke Bellos and {van der Velden}, {Vincent H. J.} and Westers, {Theresia M.} and Leonie Saft and Robin Ireland",

note = "Funding Information: Peter Valent was supported by the Austrian Science Fund (FWF) project F4704. Arjan A. van de Loosdrecht, Carolien Duetz, Nicolas Chapuis, and Michaela Fontenay are supported in part by research funding from MDS-RIGHT, which has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No 634789—“Providing the right care to the right patient with MyeloDysplastic Syndrome at the right time”. Funding Information: Peter Valent was supported by the Austrian Science Fund (FWF) project F4704. Arjan A. van de Loosdrecht, Carolien Duetz, Nicolas Chapuis, and Michaela Fontenay are supported in part by research funding from MDS‐RIGHT, which has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No 634789—“Providing the right care to the right patient with MyeloDysplastic Syndrome at the right time”. Funding Information: Horizon 2020; European Union; Austrian Science Fund, Grant/Award Number: F4704 Funding information Publisher Copyright: {\textcopyright} 2021 The Authors. Cytometry Part B: Clinical Cytometry published by Wiley Periodicals LLC on behalf of International Clinical Cytometry Society.",

year = "2023",

month = jan,

day = "15",

doi = "https://doi.org/10.1002/cyto.b.22044",

language = "English",

volume = "104",

pages = "77--86",

journal = "Cytometry Part B - Clinical Cytometry",

issn = "1552-4949",

publisher = "Wiley-Liss Inc.",

number = "1",

}

van de Loosdrecht, AA, Kern, W, Porwit, A, Valent, P, Kordasti, S, Cremers, E, Alhan, C , Duetz, C, Dunlop, A, Hobo, W, Preijers, F, Wagner-Ballon, O, Chapuis, N, Fontenay, M, Bettelheim, P, Eidenschink-Brodersen, L, Font, P, Johansson, U, Loken, MR, te Marvelde, JG, Matarraz, S, Ogata, K, Oelschlaegel, U, Orfao, A, Psarra, K, Subirá, D, Wells, DA, Béné, MC, Della Porta, MG, Burbury, K, Bellos, F, van der Velden, VHJ, Westers, TM, Saft, L & Ireland, R 2023, 'Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS-Flow Cytometry Working Group', Cytometry Part B - Clinical Cytometry, vol. 104, no. 1, pp. 77-86. https://doi.org/10.1002/cyto.b.22044

Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS-Flow Cytometry Working Group. / van de Loosdrecht, Arjan A.; Kern, Wolfgang; Porwit, Anna et al.
In: Cytometry Part B - Clinical Cytometry, Vol. 104, No. 1, 15.01.2023, p. 77-86.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome

T2 - A report of the European LeukemiaNet International MDS-Flow Cytometry Working Group

AU - van de Loosdrecht, Arjan A.

AU - Kern, Wolfgang

AU - Porwit, Anna

AU - Valent, Peter

AU - Kordasti, Sharham

AU - Cremers, Eline

AU - Alhan, Canan

AU - Duetz, Carolien

AU - Dunlop, Alan

AU - Hobo, Willemijn

AU - Preijers, Frank

AU - Wagner-Ballon, Orianne

AU - Chapuis, Nicolas

AU - Fontenay, Michaela

AU - Bettelheim, Peter

AU - Eidenschink-Brodersen, Lisa

AU - Font, Patricia

AU - Johansson, Ulrika

AU - Loken, Michael R.

AU - te Marvelde, Jeroen G.

AU - Matarraz, Sergio

AU - Ogata, Kiyoyuki

AU - Oelschlaegel, Uta

AU - Orfao, Alberto

AU - Psarra, Katherina

AU - Subirá, Dolores

AU - Wells, Denise A.

AU - Béné, Marie C.

AU - Della Porta, Matteo G.

AU - Burbury, Kate

AU - Bellos, Frauke

AU - van der Velden, Vincent H. J.

AU - Westers, Theresia M.

AU - Saft, Leonie

AU - Ireland, Robin

N1 - Funding Information: Peter Valent was supported by the Austrian Science Fund (FWF) project F4704. Arjan A. van de Loosdrecht, Carolien Duetz, Nicolas Chapuis, and Michaela Fontenay are supported in part by research funding from MDS-RIGHT, which has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No 634789—“Providing the right care to the right patient with MyeloDysplastic Syndrome at the right time”. Funding Information: Peter Valent was supported by the Austrian Science Fund (FWF) project F4704. Arjan A. van de Loosdrecht, Carolien Duetz, Nicolas Chapuis, and Michaela Fontenay are supported in part by research funding from MDS‐RIGHT, which has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No 634789—“Providing the right care to the right patient with MyeloDysplastic Syndrome at the right time”. Funding Information: Horizon 2020; European Union; Austrian Science Fund, Grant/Award Number: F4704 Funding information Publisher Copyright: © 2021 The Authors. Cytometry Part B: Clinical Cytometry published by Wiley Periodicals LLC on behalf of International Clinical Cytometry Society.

PY - 2023/1/15

Y1 - 2023/1/15

N2 - This article discusses the rationale for inclusion of flow cytometry (FCM) in the diagnostic investigation and evaluation of cytopenias of uncertain origin and suspected myelodysplastic syndromes (MDS) by the European LeukemiaNet international MDS Flow Working Group (ELN iMDS Flow WG). The WHO 2016 classification recognizes that FCM contributes to the diagnosis of MDS and may be useful for prognostication, prediction, and evaluation of response to therapy and follow-up of MDS patients.

AB - This article discusses the rationale for inclusion of flow cytometry (FCM) in the diagnostic investigation and evaluation of cytopenias of uncertain origin and suspected myelodysplastic syndromes (MDS) by the European LeukemiaNet international MDS Flow Working Group (ELN iMDS Flow WG). The WHO 2016 classification recognizes that FCM contributes to the diagnosis of MDS and may be useful for prognostication, prediction, and evaluation of response to therapy and follow-up of MDS patients.

KW - ELN

KW - consensus

KW - flow cytometry

KW - myelodysplastic syndromes

KW - standardization

UR - http://www.scopus.com/inward/record.url?scp=85112380647&partnerID=8YFLogxK

U2 - https://doi.org/10.1002/cyto.b.22044

DO - https://doi.org/10.1002/cyto.b.22044

M3 - Article

C2 - 34897979

SN - 1552-4949

VL - 104

SP - 77

EP - 86

JO - Cytometry Part B - Clinical Cytometry

JF - Cytometry Part B - Clinical Cytometry

IS - 1

ER -

van de Loosdrecht AA, Kern W, Porwit A, Valent P, Kordasti S, Cremers E et al. Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS-Flow Cytometry Working Group. Cytometry Part B - Clinical Cytometry. 2023 Jan 15;104(1):77-86. Epub 2021. doi: https://doi.org/10.1002/cyto.b.22044

Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS-Flow Cytometry Working Group

Abstract

Keywords

Access to Document

Other files and links

Cite this